Loading...
NewAmsterdam Pharma Company N.V.
NAMSW•NASDAQ
Healthcare
Biotechnology
$12.20
$-0.36(-2.87%)
NewAmsterdam Pharma Company N.V. (NAMSW) Financial Performance & Income Statement Overview
Review NewAmsterdam Pharma Company N.V.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
257.001%
↑ 257.001%
Operating Income Growth
-6.37%
↓ 6.37%
Net Income Growth
-36.54%
↓ 36.54%
Operating Cash Flow Growth
-12.28%
↓ 12.28%
Operating Margin
-402.49%
↓ 402.49%
Gross Margin
100.00%
↑ 100.00%
Net Profit Margin
-397.45%
↓ 397.45%
ROE
-32.95%
↓ 32.95%
ROIC
-24.40%
↓ 24.40%
NewAmsterdam Pharma Company N.V. (NAMSW) Income Statement & Financial Overview
Review NewAmsterdam Pharma Company N.V.'s (NAMSW) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $12.77M | $29.11M | $2.13M | $1.30M |
| Cost of Revenue | $0.00 | $0.00 | $17738.00 | $0.00 |
| Gross Profit | $12.77M | $29.11M | $2.11M | $1.30M |
| Gross Profit Ratio | $1.00 | $1.00 | $0.99 | $1.00 |
| R&D Expenses | $34.90M | $35.70M | $35.83M | $39.32M |
| SG&A Expenses | $24.31M | $17.28M | $15.38M | $13.39M |
| Operating Expenses | $56.001M | $54.11M | $43.09M | $91.05M |
| Total Costs & Expenses | $56.001M | $53.48M | $43.09M | $91.05M |
| Interest Income | $4.49M | $4.44M | $4.55M | $2.86M |
| Interest Expense | -$3.21M | $1.14M | $853145.00 | $667016.00 |
| Depreciation & Amortization | $51000.00 | $28000.00 | $17736.00 | $13901.00 |
| EBITDA | -$111.69M | -$23.84M | -$49.06M | -$54.57M |
| EBITDA Ratio | -$8.75 | -$0.82 | -$23.06 | -$39.59 |
| Operating Income | -$43.23M | -$24.36M | -$49.08M | -$51.42M |
| Operating Income Ratio | -$3.38 | -$0.84 | -$23.07 | -$39.60 |
| Other Income/Expenses (Net) | -$48.95M | $7.72M | $12.67M | -$35.48M |
| Income Before Tax | -$92.18M | -$16.65M | -$36.41M | -$86.89M |
| Income Before Tax Ratio | -$7.22 | -$0.57 | -$17.12 | -$66.93 |
| Income Tax Expense | $0.00 | -$1000.00 | $0.00 | $0.00 |
| Net Income | -$92.18M | -$16.65M | -$36.41M | -$86.89M |
| Net Income Ratio | -$7.22 | -$0.57 | -$17.12 | -$66.93 |
| EPS | -$0.98 | -$0.18 | -$0.38 | -$0.98 |
| Diluted EPS | -$0.98 | -$0.18 | -$0.38 | -$0.98 |
| Weighted Avg Shares Outstanding | $94.36M | $94.75M | $94.71M | $82.16M |
| Weighted Avg Shares Outstanding (Diluted) | $94.36M | $94.75M | $94.71M | $82.16M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan